Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effects of Music Intervention on Quality of Life, Anxiety, and Fatigue Among Patients With Breast Cancer: A Randomized Controlled Trial.

Oncology nursing forum·2024
Same author

Association between Spinal Cord Injury and Alcohol Dependence: A Population-Based Retrospective Cohort Study.

Journal of personalized medicine·2022
Same author

The Impact of Direct-Acting Antiviral Therapy on the Risk of Recurrence after Curative Resection in Patients with Hepatitis-C-Virus-Related Early Stage Hepatocellular Carcinoma.

Medicina (Kaunas, Lithuania)·2022
Same author

Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study.

Frontiers in oncology·2022
Same author

Concurrent Cholecystectomy Is Associated with a Lower Risk of Recurrence after Curative Resection in Early-Stage Hepatocellular Carcinoma: A 10 Year Observational Single-Center Study.

Journal of personalized medicine·2021
Same author

Preoperative ALBI grade predicts the outcomes in non-B non-C HCC patients undergoing primary curative resection.

BMC gastroenterology·2021

Related Experiment Video

Updated: Jun 21, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

[Failure mode and effect analysis: application in chemotherapy].

Ching-Hui Chuang1, Sheu-Wen Chuang

  • 1School of Medicine & Public Health, University of Newcastle, Australia.

Hu Li Za Zhi the Journal of Nursing
|July 28, 2009
PubMed
Summary
This summary is machine-generated.

Failure Mode and Effect Analysis (FMEA) identifies potential patient safety risks in healthcare. Applying FMEA to chemotherapy revealed issues with procedures, communication, and nurse training, enabling proactive improvements.

More Related Videos

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Related Experiment Videos

Last Updated: Jun 21, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Area of Science:

  • Healthcare Quality Improvement
  • Patient Safety Research
  • Clinical Risk Management

Context:

  • Medical institutions face increasing pressure to enhance patient safety.
  • Failure Mode and Effect Analysis (FMEA) is a proactive risk assessment tool.
  • FMEA is widely adopted in healthcare, promoted by organizations like JCAHO since 2002.

Purpose:

  • To assess and analyze clinical error events using FMEA.
  • To identify failure points in chemotherapy processes.
  • To proactively address causes of problems and prioritize improvement strategies.

Summary:

  • FMEA application in chemotherapy identified three key failure points: inadequate standard operating procedures (SOPs), communication barriers, and insufficient nurse training.
  • This proactive approach aims to predict and mitigate potential system failures.
  • The method is effective in minimizing errors across industries, including healthcare.

Impact:

  • Expected to enhance healthcare practitioners' sensitivity and proactive capabilities in high-risk situations.
  • Aims to improve overall patient care safety levels.
  • Facilitates targeted interventions to reduce clinical errors and enhance system reliability.